NewLink Genetics Corp (NLNK.O) said it entered into an agreement with Roche Holding AG (ROG.VX) to develop NewLink’s cancer immunotherapy, making the Ebola vaccine developer eligible to receive over $1 billion in milestone payments.
NewLink’s shares jumped nearly 30 percent before the bell on Monday.
{iframe}http://www.reuters.com/article/2014/10/20/us-newlink-genetics-roche-cancer-idUSKCN0I914Z20141020{/iframe}